Nanobody is a heavy chain only, single domain antibody. Compared to conventional antibodies, nanobodies are smaller in size, approximately 1/10 the size of regular antibodies. This reduced size provides several advantages, such as improved tissue permeability, and enhanced antigen accessibility, leading to increased targeting ability. Above all, it’s easy to engineer to target specific antigen due its simple structure.
Shaperon, Inc. has developed an efficient and sensitive in-house screening system that allows for the rapid selection and production of nanobodies within a time-frame of just 9 weeks. Hudson Therapeutics, Inc. will leverage Shaperon's proprietary nanobody technology to accelerate nanobody pipeline development in the U.S.
CD-47/PD-L1 Bi-Specific Nanobody
Blockade of dual immune checkpoint inhibitory signals with targeting CD47 (innate immunity) & PD-L1 (adoptive immunity)
Excellent safety by unique structure with No RBC binding
© 2023 Hudson Therapeutics, Inc.
The information presented on this website is derived from the official website of our parent company, Shaperon, Inc. This site is designed exclusively to showcase Hudson Therapeutics, Inc. to potential investors and partners. Please note that we are not responsible for any misuse of the content outside its intended purpose.